Abstract P1103: A Combinatorial Stem Cell Therapy Using HiPSC-derived Cardiomyocytes And HiPSC-derived Mesenchymal Stem Cells For Cardiac Regeneration
Divya Sridharan,Syed Baseeruddin Alvi,Muhamad Mergaye,Abbey Forehand,Uzair Ahmed,Mahmood Khan
DOI: https://doi.org/10.1161/res.133.suppl_1.p1103
IF: 23.213
2023-08-04
Circulation Research
Abstract:Introduction: Myocardial infarction (MI) results in the death of nearly a billion cardiomyocytes in the heart. While conventional therapies alleviate the injury to some extent, they do not induce myocardial regeneration. On the other hand, transplantation of stem cells and their derived differentiated cells like hiPSC-derived cardiomyocytes (hiPSC-CMs) and hiPSC-derived mesenchymal stem cells (hiPSC-MSCs) have the potential to promote myocardial regeneration by direct (replacing dead cardiomyocytes) or indirect (paracrine) mechanisms, respectively. Hypothesis: We hypothesized that following co-transplantation of hiPSC-CMs and hiPSC-MSCs in ischemic hearts, hiPSC-MSCs will release paracrine factors to promote angiogenesis, reduce fibrosis, and improve cardioprotection and engraftment of transplanted hiPSC-CMs. Results: We cultured hiPSC-CMs and hiPSC-MSCs at different ratios, 1:1, 1:2 and 1:3, respectively. We observed improved contractility (MEA, and calcium transients) in the hiPSC-CM + hiPSC-MSC co-cultures, as compared to single cell-type cultures. Additionally, following exposure to hypoxia (1%O 2 ), we observed increased survival of hiPSC-CMs when co-cultured with hiPSC-MSCs (TUNEL assay). Furthermore, intramyocardial transplantation of (a) 1.5 х 10 6 hiPSC-CMs, (b) 1.5 х 10 6 hiPSC-MSCs or (c) 1.5 х 10 6 hiPSC-CMs + hiPSC-MSCs (3:1) in a mouse MI model, resulted in an improved cardiac function, LVEF (p < 0.01) and FS (p<0.01) in all animals receiving cell transplantation as compared to MI only group. Additionally, we observed efficient engraftment (immunostaining of human-specific markers, cTnT and HNA) of transplanted hiPSC-CMs in both hiPSC-CM-only and hiPSC-CM + hiPSC-MSC groups up to 4 weeks post-MI. We also observed increased neoangiogenesis (α-SMA, vWF) near the graft in the hiPSC-MSC-only and hiPSC-CM + hiPSC-MSC groups, as compared to control and hiPSC-CM-only groups. Lastly, a significant reduction in fibrosis (Masson-trichrome staining) was seen following transplantation of hiPSC-CMs + hiPSC-MSCs, compared to the control animals. Conclusion: Overall, our results established that a combinatorial stem therapy using hiPSC-CMs and hiPSC-MSCs for cardiac regeneration post-MI.
cardiac & cardiovascular systems,peripheral vascular disease,hematology